Becton, Dickinson And Company

Becton, Dickinson And Company's BD Biosciences division (BDB) operates as a prime contractor supplying flow cytometry instrumentation, maintenance services, and laboratory reagents to federal health and research agencies on a full-and-open competition basis without set-aside posture. Based in Milpitas, California as a subsidiary of the multinational Becton, Dickinson And Co. parent, BD Biosciences is a large for-profit manufacturer competing across federal civilian healthcare and research procurement with a footprint spanning 111 customer agencies, though customer concentration runs steep toward the National Institutes of Health.

BD Biosciences' federal work centers on flow cytometry systems and consumables—proprietary diagnostic instruments and cell-analysis reagents that dominate the company's sales to government. Representative work includes a $4.5 million purchase order with the National Cancer Institute for maintenance of 23 government-owned BD flow cytometers with two annual preventive maintenance inspections, unlimited Monday-Friday technician visits, 48-hour emergency response, unlimited telephone support, and OEM parts and labor (awarded July 2, 2026, running through July 1, 2030); a $4.08 million Vaccine Research Center order for eight FACSymphony A5 SE cell analyzers to maintain research infrastructure continuity (September 2024); a $1.51 million Department of Veterans Affairs order for a 10-color flow cytometry instrumentation system with sample and reagent prep equipment (April 2026); and a $800,000 National Cancer Institute lease-and-maintenance contract for BD-owned equipment, preventive maintenance of government-owned systems, and consumables (September 2024). The company also supplies reagent kits for genomics applications—including a $20.1 thousand Department of Agriculture order for BD Rhapsody high-throughput reagent kits compatible with single-nuclei sequencing and ATAC-seq workflows (April 2026).

Customer concentration skews toward NIH: the National Institute of Allergy and Infectious Diseases leads by count (373 awards, $45.4 million combined potential value), followed by the National Cancer Institute (534 awards, $31.3 million), and the Food and Drug Administration (185 awards, $17.3 million). The Department of Veterans Affairs Veterans Integrated Service Network 22 ranks fourth by dollars ($14.6 million across 103 awards), and the National Heart Lung and Blood Institute fifth ($13.7 million, 207 awards). The top five customers account for roughly 22% of the vendor's combined potential value—a concentration signal reflecting the NIH enterprise's reliance on BD's proprietary flow cytometry platforms for biomedical research across dozens of institutes and centers.

BD Biosciences' vehicle positioning spans the Federal Supply Schedule and Multiple Award Schedule. The company holds a General Services Administration Federal Supply Schedule contract (GS24F2044D) supporting 2,458 task orders worth $86.2 million in combined potential value—the single largest vehicle in the portfolio. The Multiple Award Schedule vehicle has generated 427 task orders ($28 million combined potential value). Single-award indefinite delivery contracts with the Veterans Affairs (VISN 17, $1.57 million through May 2028 for flow cytometry systems and reagents) and the Defense Health Agency ($4 million through September 2030 for laboratory reagents) establish streamlined procurement frameworks. A Blanket Purchase Agreement with the VA VISN 2 for blood culture analyzers and supplies carries a ceiling of $678,674.70 through October 2030. These vehicles enable task-order issuance without re-competition, positioning BD for sustained ordering as agencies refresh equipment or replenish consumables.

Activity has remained stable—141 prime awards in 2024, declining to 91 in 2025 and 48 so far in 2026 (reflecting the July 2026 data snapshot)—with 108 awards reaching ultimate completion within the next 24 months and carrying combined potential value of $18 million, representing near-term recompete exposure. The recompete cliff is modest relative to the portfolio, suggesting relatively steady-state procurement rather than concentration of large multi-year awards expiring synchronously.

BD Biosciences operates as a 100% prime contractor in this footprint; the two sub-awards listed (one with Johns Hopkins APL on DARPA research support, one with Triad National Security for Los Alamos National Laboratory equipment procurement) represent negligible sub engagement. The company does not rely on subcontractors for federal service delivery; SCI-reportable service contracts captured in the source show minimal invoiced revenue ($735 thousand across FY2023–FY2024 with fewer than one FTE on average), indicating that the vast majority of BD Biosciences' federal work falls outside the $150,000 SCI reporting threshold and is concentrated in goods procurement (flow cytometry systems and reagents) rather than services. Government-paid hourly rates on SCI-reportable contracts run a median of $1,705.96/hr, with rates spanning $430.84/hr at the tenth percentile to $3,590.45/hr at the ninety-fifth percentile, reflecting technical service and installation labor where such contracts do exist.

BD Biosciences' federal footprint is characterized by repetitive, consumables-and-maintenance purchasing tied to a standardized flow cytometry platform ecosystem that the company manufactures and controls as original equipment maker. Agencies—particularly within NIH and VA—issue purchase orders and task orders for system maintenance, reagent replenishment, and equipment upgrades under existing vehicles rather than competing new requirements, yielding a high-volume, low-friction procurement model. The company competes on technical compatibility, past performance, and manufacturer authority rather than cost or socioeconomic designation, positioning it as a locked-in incumbent vendor across civilian federal biomedical research infrastructure.